Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vericel Corporation - Common Stock (NQ: VCEL )

52.85 +0.33 (+0.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 387,239
Open 52.31
Bid (Size) 46.00 (1)
Ask (Size) 60.00 (1)
Prev. Close 52.52
Today's Range 52.30 - 53.56
52wk Range 39.12 - 63.00
Shares Outstanding 46,631,158
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025
From Vericel Corporation
Via GlobeNewswire
What 7 Analyst Ratings Have To Say About Vericel
Via Benzinga

Performance

YTD
-4.10%
-4.10%
1 Month
-11.50%
-11.50%
3 Month
-8.50%
-8.50%
6 Month
+0.53%
+0.53%
1 Year
+10.10%
+10.10%

More News

Read More
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Beyond The Numbers: 5 Analysts Discuss Vericel Stock
Via Benzinga
Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets
From Vericel Corporation
Via GlobeNewswire
Earnings Preview For Vericel
Via Benzinga
The Analyst Verdict: Vericel In The Eyes Of 7 Experts
Via Benzinga
Expert Ratings For Vericel
Via Benzinga
Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025
From Vericel Corporation
Via GlobeNewswire
Vericel Stock Sees RS Rating Shoot Higher
Via Investor's Business Daily
Smaller Cap Biotechs Are In Season: How Are We Doing?
Via Talk Markets
Vericel Reports Third Quarter 2024 Financial Results
From Vericel Corporation
Via GlobeNewswire
The Latest Analyst Ratings For Vericel
Via Benzinga
A Glimpse Into The Expert Outlook On Vericel Through 4 Analysts
Via Benzinga
Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024
From Vericel Corporation
Via GlobeNewswire
Vericel Announces FDA Approval and Commercial Availability of MACI Arthro
From Vericel Corporation
Via GlobeNewswire
Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024
From Vericel Corporation
Via GlobeNewswire
Apple To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Vericel Reports Second Quarter 2024 Financial Results
From Vericel Corporation
Via GlobeNewswire
Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer
From Vericel Corporation
Via GlobeNewswire
Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024
From Vericel Corporation
Via GlobeNewswire
Trading SMID Biotech Stocks In A Volatile Market
Via Talk Markets
The 3 Highest-Rated Medical Stocks You Can Buy Today
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.